{"classes":[{"categories":[{"measurements":[{"comment":"Not evaluable due to insufficient number of events","groupId":"OG000","lowerLimit":"13.9","upperLimit":"NA","value":"22"},{"groupId":"OG001","lowerLimit":"8.8","upperLimit":"21.3","value":"12"},{"groupId":"OG002","lowerLimit":"6.2","upperLimit":"14.5","value":"10.429"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"83"},{"groupId":"OG002","value":"83"}],"units":"Participants"}],"description":"DOR, based on IMWG criteria per blinded IRC assessment, is defined as the duration from the first documented onset of PR or better (iCR or sCR or CR or VGPR) to the date of first documented disease progression or death due to multiple myeloma.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 20 mg panobinostat TIW, 2 weeks on/1 week off in combination with subcutaneous bortezomib and oral dexamethasone.","id":"OG000","title":"Arm A - Panobinostat (20 mg, TIW)"},{"description":"Participants received 20 mg panobinostat BIW, 2 weeks on/1 week off in combination with subcutaneous bortezomib and oral dexamethasone.","id":"OG001","title":"Arm B - Panobinostat (20 mg, BIW)"},{"description":"Participants received 10 mg panobinostat TIW, 2 weeks on/1 week off in combination with subcutaneous bortezomib and oral dexamethasone.","id":"OG002","title":"Arm C - Panobinostat (10 mg, TIW)"}],"paramType":"MEDIAN","populationDescription":"Full analysis set (FAS): all participants to whom study treatment was assigned by randomization.","reportingStatus":"POSTED","timeFrame":"Up to 5.2 years","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}